Key Sequencing Services and Genetics Test

CRYSTA-NIPT- NON-INVASIVE PRE-NATAL TESTING

Redcliffe Life Science combines Next Generation Sequencing (NGS) with the latest analysis procedure to conduct various genetic test services, including the prenatal gene test for pregnant women and individual health management test and cancer test, from which we can know whether the baby is perfectly healthy or whether the individual is vulnerable to diseases. With the gene test, we can also determine the epigenetic codes and learn the health conditions of individuals, so as to assist in preparing for their future medical state and improve life quality.

CRYSTA-NIPT-PLUS

In addition to NIPT, we can test for micro-deletions too.Microdeletion syndromes are caused by the deletion of small portion of genetic material during chromosome duplication. In general, the loss of the genetic material carry risks to childs health and development, such as congenital heart defect, delay development of cognitive impairment, autoimmune disease, etc. Yourgene offer NIPT+ – Microdeletion screen test that includes screening for up to 20 Microdeletions.

CRYSTA-Preimplantation Genetic Diagnosis (PGD)/Screening (PGS) With IVF

CRYSTA-PGS (Preimplantation genetic screenings now available for:

  • Beta Thalessemia Trait
  • Sickle Cell
  • Cystic Fibrosis
  • SMA 1
  • Tay Sachs
  • Fragile X
CRYSTA-ONC Hereditary Cancer Testing

Common Hereditary Cancers Panel analyzes over 400 genes associated with cancers of the breast, ovary, uterus, prostate, and gastrointestinal system, which includes the stomach, colon, rectum, small bowel, and pancreas. The panel is designed to maximize diagnostic yield for individuals with a personal or family history of mixed cancers affecting these organ systems.

Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.

Inherited Disorders

Redcliffe offers testing of Inherited Disorders Focused Exome Testing across over 6000 genes validated using a highly targeted design that enables analysis of only the disease associatedtargets providing deep coverage even on a benchtop sequencer. This design provides 20 or more reads for 95% of targets at 1.5Gb (100x) of sequencing and 98% of targets with 3Gb (200x) of sequencing enabling superior coverage of disease-associated regions making it the ONLY panel across PAN India that offers the most extensive coverage.

Clinical Oncology and Liquid-Biopsy (Blood)

Only testing facility in India on lines of FDA Genetic profiling of FFPE cancer tissue samples, Blood Plasma and more. All tests are conducted by targeted next-generation sequencing (NGS) and is now becoming a daily routine in oncology clinical applications.

  • Simultaneous detection of hundreds of variants across hundred of genes relevant to solid tumors
  • Targets relevant hotspots, SNVs, indels, CNVs, and gene fusions from DNA or RNA in a single workflow
  • Includes solid tumor genes targeted by on-market oncology drugs and published evidence
  • Content driven by the Knowledgebase, similar to the FDA panel which includes content aligned to approved therapies and indications.
To provide researchers and healthcare professionals with quality genomic data
at rapid turnaround times with industry leading pricing.

About Us

WHO WE ARE

Redcliffe Lifesciences takes pride in its principal business processes endeavours which go back to over a decade of investments in the Healthcare orb. We expend our resources and retain Global expertise to deliver Healthcare solutions through Molecular Genomics, Research paving a robust and unique gateway towards Precision Medicine. Our distinct and individualised offerings in Maternal Health, Oncology, Cardiology & Inherited Disorders are advancing the ability to how we treat and are opening far-reaching therapeutic opportunities in the era of Precision Functional Medicine.

Read More

MISSION

Our mission continues to harp around global advances in science & particularly in Genomics. We shall strive to bring about novel molecular innovative solutions to help support precision healthcare through cutting edge technology and solutions that stand out to support Indian diverse population.

Read More

COMMITMENT TOWARDS QUALITY

Redcliffe pledges to select, support & supervise all its processes, stringent protocols that confirms to International Guidelines and attain or improvise on knowledge and develop voluntary, consensus-based, market relevant International Standards that support innovation and provide solutions to global challenges.

Read More

Request a Call back